BioPharma Dive June 8, 2023
Kristin Jensen

Dive Brief:

  • Upstream Bio has successfully navigated a rocky market for biotech startups to raise $200 million in fresh financing in a Series B round.
  • The company plans to use the funds to advance its experimental medicine UPB-101 into Phase 2 trials for asthma and chronic rhinosinusitis with nasal polyps and is also preparing for “a swift transition to Phase 3 development.” The drug is currently in Phase 1b testing for asthma.
  • Enavate Sciences and Venrock Healthcare Capital Partners led the latest round of financing, which also attracted new investors Bain Capital Life Sciences and Wellington Management. Enavate’s Edd Fleming and Venrock’s Alex Rosen joined Upstream’s board as well, the company said Thursday.

Dive Insight:

Led by Samantha...

Today's Sponsors

LEK
Upfront Healthcare

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Related Articles:
Big Food vs. Big Pharma: Companies bet on snacking just as weight loss drugs boom
Preventative Drug Lists Led to More Affordable Asthma Medication
Lawsuits To Block Medicare Drug Price Negotiations Are Very Unpopular Among Voters
Avalyn’s New Twist on Older Lung Disease Drugs Attracts $175M for Clinical Trials
GLP-1 drugs are transforming diabetes, obesity and more. Could a Nobel be next?

Share This Article